Boardroom Alpha
Boardroom Alpha
AMTX · Current Report (Form 8-K) · Filed February 19, 2026

Aemetis Inc — Current Report (Form 8-K)

Form
8-K
Filed
February 19, 2026
Period
Feb 18, 2026
Ticker
AMTX
Accession
0001437749-26-004619
Boardroom Alpha · Filing insights

Stockholders approved increasing authorized common stock to 140M and total authorized capitalization to 205M. The proposal to reduce authorized preferred stock failed.

About Aemetis Inc
Market cap
$182M
1Y TSR
+29.8%
3Y TSR
−25.0%
Board grade
C-
Sector
Energy
CEO
Eric A McAfee
Last annual meeting: May 20, 2026 · View full Aemetis Inc profile →
amtx20260206c_8k.htm
--12-31
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): February 18, 2026
 
Aemetis, Inc.
Exact name of registrant as specified in its charter
 
Delaware
001-36475
26-1407544
State or other jurisdiction of incorporation
Commission File Number
IRS Employer Identification Number
 
20400 Stevens Creek Blvd., Suite 700
Cupertino, CA 95014
(408) 213-0940
Registrant's address and telephone number of principal executive office
 
N/A
Former name or former address, if changed since last report
 
Common Stock, par value $0.001
AMTX
NASDAQ Global Market
Title of class of registered securities Trading Symbol Name of exchange on which registered
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter)
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
 

 
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
 
On February 18, 2026, Aemetis, Inc. (the "Company") filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company's capital stock from 145,000,000 shares to 205,000,000 shares, which reflects the increase in the number of authorized shares of the Company’s common stock, par value $0.001 per share (the "Common Stock"), from 80,000,000 to 140,000,000 shares. A copy of the Certificate of Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Item 5.07  Submission of Matters to a Vote of Security Holders.
 
The Company held a Special Meeting of Stockholders on February 18, 2026. The following proposals were voted on by the Company's stockholders, with the results set forth for each proposal:
 
Proposal 1:  Decrease of Authorized Preferred Stock
 
For
Against
Abstain
Broker Non-Votes
26,150,519
1,265,702
76,173 13,444,173
 
The amendment to the Company's Certificate of Incorporation to decrease the number of authorized shares of preferred stock, par value $0.001, from 65,000,000 to 5,000,000 shares has not been approved by the requisite vote of the Company's stockholders.
 
Proposal 2:  Increase of Authorized Common Stock
 
For
Against
Abstain
Broker Non-Votes
35,827,828 4,952,652 156,087
0
 
The amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of common stock, par value $0.001, from 80,000,000 to 140,000,000 has been approved by the requisite vote of the Company's stockholders.
 
Proposal 3:  Adjourn the Special Meeting
 
For
Against
Abstain
Broker Non-Votes
36,981,214 3,536,067 419,286
0
 
The proposal to provide the Company with discretion to adjourn the Special Meeting to a later date for further solicitation and voting of proxies if there are not sufficient votes to approve Proposal 1 or Proposal 2 has been approved by the requisite vote of the Company's stockholders.
 
Item 8.01 Other Events.
 
The Company is filing this Current Report on Form 8-K to provide an updated description of the Company’s capital stock as set forth in Exhibit 99.1 hereto and incorporated by reference herein. The updated description of the Company’s capital stock modifies and supersedes any prior description of the Company’s capital stock in any registration statement filed with the Securities and Exchange Commission (the “Commission”) and will be available for incorporation by reference into certain of the Company’s filings with the Commission pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended, including registration statements.
 
The Company is also providing a legal opinion of its counsel, Allen Overy Shearman Sterling US LLP, regarding the legality of the shares of the Common Stock having an aggregate offering price of up to $210,000,000 (the “Placement Shares”) that may be offered and sold from time to time through H.C. Wainwright & Co., LLC pursuant to the At Market Issuance Sales Agreement, dated January 26, 2021, as amended.
 
The Placement Shares will be issued pursuant to the Company’s Registration Statement on Form S-3 (Registration No. 333-281457), as amended from time to time (the “Registration Statement”). The legal opinion is filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated by reference into the Registration Statement. 
 
This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
 
Item 9.01 Financial Statements and Exhibits.
 
(d) Exhibits.
 
Exhibit No.
Description
3.1
5.1
23.1
Consent of Allen Overy Shearman Sterling US LLP (included in Exhibit 5.1)
99.1 Description of Capital Stock
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
SIGNATURE
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.
 
  Aemetis, Inc.
   
   February 19, 2026
/s/ Eric A. McAfee
 
Eric A. McAfee
 
Chairman and Chief Executive Officer
 
 
 
 
From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Aemetis Inc (AMTX)

Reference

Frequently asked questions

When did Aemetis Inc file this 8-K?
Aemetis Inc (AMTX) filed this Current Report (Form 8-K) with the SEC on February 19, 2026. The accession number assigned by EDGAR is 0001437749-26-004619.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders approved increasing authorized common stock to 140M and total authorized capitalization to 205M. The proposal to reduce authorized preferred stock failed. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Aemetis Inc's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Aemetis Inc has filed under CIK 738214, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer